Have questions about RSV or maternal vaccination with ABRYSVO^®?

Is my baby at risk for RSV?

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants. The risk of your baby being admitted to hospital with RSV is 16x higher than the flu. RSV is very easily spread to people in hospitals, at home, and in nurseries. Babies are most at risk for hospitalization due to RSV when they are 6 months old or younger.

Infants and young children can have a higher risk of RSV if they:

• Are born prematurely
• Are up to 12 months old, especially those 6 months and younger
• Are less than 2 years old with chronic lung disease or heart disease present from birth
• Have weakened immune systems
• Have neuromuscular disorders, including difficulty swallowing or clearing mucus from the chest

What could happen if my baby gets RSV?

RSV may cause a baby to develop a severe wet cough, wheezing, difficulty breathing, or even pneumonia. Babies who become sick with severe RSV may need to be admitted to the hospital. There is a risk that babies who become sick with RSV may have problems with their lungs later in life including asthma.

What could I do to help protect my baby against RSV?

Babies are most vulnerable to getting sick from RSV during their first 6 months. That's because a baby's immune system isn't fully developed when they are born and needs time to grow stronger. One way to help protect newborn babies is to vaccinate pregnant women during weeks 32 through 36 of pregnancy. Pfizer’s ABRYSVO is a vaccine for pregnant women that helps protect your baby against RSV from birth through the first 6 months of their life.

How does getting vaccinated with ABRYSVO while pregnant help protect my baby?

Pfizer’s ABRYSVO helps your body create RSV antibodies that are passed from you to your unborn baby, and helps protect your baby from RSV from birth through 6 months.

How was Pfizer’s ABRYSVO studied in pregnant women?

ABRYSVO was studied in clinical trials including over 7,000 pregnant women and their babies, where 3,695 pregnant women received ABRYSVO and 3,697 received a placebo.

If I’m pregnant, when should I get Pfizer’s ABRYSVO?

The CDC recommends ABRYSVO if you are 32 through 36 weeks pregnant during September through January (in most of the continental United States). However, there are areas in the U.S., including southern Florida, Alaska, Hawaii, and the U.S. territories, where RSV does not follow the typical seasonal patterns and the recommended months for maternal vaccination may differ.

Talk to your OB to learn more about how to protect your baby against RSV during their first RSV season and whether ABRYSVO is right for you.

Check your eligibility >

What were the most common side effects of Pfizer’s ABRYSVO in its clinical trial?

Pregnant women who received ABRYSVO most commonly reported pain at the injection site, headache, muscle pain, and nausea.

Jaundice, also known as temporary yellowing of the eyes and skin, was seen in 7.2% of infants in the ABRYSVO group and 6.7% in the placebo group.

Low birth weight was observed in 5.1% of infants in the ABRYSVO group versus 4.4% in the placebo group.

What are some questions I can ask my OB or other healthcare provider about Pfizer’s ABRYSVO?

• Am I eligible to receive ABRYSVO?
• When during my pregnancy should I get an RSV vaccine?
• What are the risks with ABRYSVO?
• How long may my baby be protected if I get vaccinated with ABRYSVO?